GlassScriptPhysician profile
Barbara A Browder
NPI 1740702901
$2,240.12
in general payments reported to CMS, 2019-2025
17 companies · $714 in 2025
The $714 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $92.20 · 2022: $129 · 2024: $1,305 · 2025: $714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,019.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $496.84 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $313.79 | 2024-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $225.85 | 2024-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $205.09 | 2024-2025 | Rexulti |
| Alkermes, INC. | $192.55 | 2024-2025 | Lybalvi, Aristada |
| Janssen Pharmaceuticals, INC | $156.07 | 2024-2025 | Spravato |
| Lundbeck LLC | $138.33 | 2024-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $112.46 | 2022 | |
| Corium, LLC | $108.46 | 2024-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $107.47 | 2024-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $49.69 | 2021-2025 | Trintellix |
| Tris Pharma INC | $34.87 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $27.67 | 2024 | Austedo Xr |
| Tempus Ai, INC | $23.51 | 2024 | Tempus Pixel |
| Ironshore Pharmaceuticals INC. | $18.95 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $14.85 | 2025 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $13.67 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Browder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.